Whitney Graybill to Ovarian Neoplasms
This is a "connection" page, showing publications Whitney Graybill has written about Ovarian Neoplasms.
Connection Strength
1.707
-
Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma. Gynecol Oncol. 2017 07; 146(1):11-15.
Score: 0.483
-
Vintafolide: a novel targeted agent for epithelial ovarian cancer. Future Oncol. 2014 Mar; 10(4):541-8.
Score: 0.390
-
Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial. Gynecol Oncol. 2022 09; 166(3):494-502.
Score: 0.174
-
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019 12 19; 381(25):2391-2402.
Score: 0.143
-
Racial disparities in treatment and survival from ovarian cancer. Cancer Epidemiol. 2019 02; 58:77-82.
Score: 0.136
-
State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecol Oncol. 2015 Aug; 138(2):223-6.
Score: 0.107
-
Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res. 2015 Jan 15; 21(2):448-59.
Score: 0.102
-
Detection and monitoring of ovarian cancer. Clin Chim Acta. 2013 Jan 16; 415:341-5.
Score: 0.089
-
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011 Nov 02; 103(21):1596-612.
Score: 0.082